- Home
- JSPR vs EDAP Comparison
JSPR vs EDAP Comparison
Compare JSPR & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- EDAP
- Stock Information
- Founded
- JSPR 2018
- EDAP 1979
- Country
- JSPR United States
- EDAP France
- Employees
- JSPR 64
- EDAP N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- JSPR Health Care
- EDAP Health Care
- Exchange
- JSPR Nasdaq
- EDAP Nasdaq
- Market Cap
- JSPR 47.6M
- EDAP 46.7M
- IPO Year
- JSPR N/A
- EDAP 1997
- Fundamental
- Price
- JSPR $2.86
- EDAP $1.48
- Analyst Decision
- JSPR Buy
- EDAP Buy
- Analyst Count
- JSPR 12
- EDAP 3
- Target Price
- JSPR $30.78
- EDAP $8.50
- AVG Volume (30 Days)
- JSPR 293.2K
- EDAP 68.1K
- Earning Date
- JSPR 08-13-2025
- EDAP 08-28-2025
- Dividend Yield
- JSPR N/A
- EDAP N/A
- EPS Growth
- JSPR N/A
- EDAP N/A
- EPS
- JSPR N/A
- EDAP N/A
- Revenue
- JSPR N/A
- EDAP $67,840,467.00
- Revenue This Year
- JSPR N/A
- EDAP N/A
- Revenue Next Year
- JSPR N/A
- EDAP N/A
- P/E Ratio
- JSPR N/A
- EDAP N/A
- Revenue Growth
- JSPR N/A
- EDAP 3.69
- 52 Week Low
- JSPR $2.27
- EDAP $1.21
- 52 Week High
- JSPR $26.05
- EDAP $4.40
- Technical
- Relative Strength Index (RSI)
- JSPR 42.31
- EDAP 57.33
- Support Level
- JSPR $2.90
- EDAP $1.30
- Resistance Level
- JSPR $3.14
- EDAP $1.43
- Average True Range (ATR)
- JSPR 0.20
- EDAP 0.09
- MACD
- JSPR 0.09
- EDAP 0.03
- Stochastic Oscillator
- JSPR 71.03
- EDAP 100.00
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.